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Abstract
Patients with coronary artery disease associated with malignancy are a difficult group of patients to treat. The ideal
approach to manage them is still controversial. Both problems can be manage by either a combined or staged
operation. The use of CPB during revascularization of the myocardium among patients with malignant disease,
may have an effect on dissimination of malignant cells. This was observed among two of our patients. We believe
that the use of off-pump technique to revascularize the myocardium is a safe approach and can be performed
either in combined or staged surgery to resect malignant disease.
Commentary
Patients with coronary artery disease associated with
malignancy are a difficult group of patients to treat. The
ideal approach to manage them is still controversial.
Both problems can be managed by either a combined or
staged operation. The real issue lies in the technique of
bypass used to revascularize the myocardium. We and
others proved that off-pump technique is a safe
approach used to revascularize the myocardium which
can be done with excision of the tumour at the same
time or in a staged surgery [1,2].
The effect of CPB on malignant cell growth and dis-
simination is not known. It is well documented that the
use of CPB has a direct inhibitory effect on both cell
mediated and humoral immunity [3] which subsequently
may affect the spread of malignant cells.
The use of standared CPB to revascularize the myo-
cardium among these patients showed contradicting
results. Most of the studies found that this technique is
safe and efficient when used in combined surgery to
treat both lung cancer and myocardial revascularization
[4,5]. Others,found that some of their patients had wide-
spread malignancy after successful operation [6].
Recently, we were confronted with two cases with cor-
onary artery disease who needed surgical myocardial
revascularization. One patient had a localized moder-
ately differentiated adenocarcinoma of the sigmoid
colon and the other patient had no known malignancy.
Both patients underwent successful myocardial revascu-
larization using conventional CPB. During follow up, the
patient with colonic cancer who was scheduled to
undergo surgery came back after 3 weeks with wide-
spread malignancy affecting the abdominal, mediastinal,
and axillary lymph nodes together with bilateral pul-
monary metastasis. The other patient was seen with
recurrent right sided pleural effusion one month after
surgery. Initially, it was thought to be a sequale of car-
diac operation. Aspiration and cytology showed evidence
of metastatic malignant cells with unknown primary.
Our observation emphasized that CPB may have a
direct effect on the spread of malignant cells and even it
may stimulate the growth of hidden malignancy. The
exact cause why malignant cells in our cases behaved in
that manner?. A previous study by Tonnesen and cow-
orkers [7] showed that the natural killer cells (N K cells)
which have spontaneous cytotoxicity against tumour
cells are inhibited during and after cardiopulmonary
bypass. Also the complement factors, lymphocytes, and
neutrophils are depleted. All these factors may explain
the spread of malignant cells.
We believe that CPB should be avoided among
patients with combined coronary artery disease and
malignancy unless both diseases are treated at the same
time. The use of off-pump bypass to revascularize the
myocardium together with excision of the tumour in
either a combined or staged approach is a safe techni-
que to avoid the spread of malignant cells.
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